Free Newsletter
Researchers test side effects of new smallpox vaccine
Researchers at the University of Kentucky are involved in a new study of an experimental smallpox vaccine being developed by Bavarian Nordic. Imvamune contains a non-replicating vaccinia virus which is intended to make the experimental vaccine safer than the existing vaccine.
Researchers are testing the vaccine's affect on patients with eczema and other inflammatory skin conditions. This population can experience life-threatening side effects when exposed to the current vaccine and researchers want to gain a better understanding of the new vaccine's impact on the same group of people. The researchers will gauge their immune response and any side effects.
There's been no outbreak of smallpox in the past 31 years. But the U.S. and other countries remain concerned that terrorist groups could develop a devastating weapon if they obtain the smallpox virus. It's only known to exist in two laboratories.
- read the report in the Kentucky Herald-Leader
Related Articles:
Bavarian Nordic reports success in breast cancer trials
Bavarian Nordic launches early trial for HIV vaccine
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




